Menu
Recruiting NCT06943807

Prospective Gastric Cancer Screening With Fecal Multi-target DNA Analysis

Observational Gastric (Stomach) Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Gastric (Stomach) Cancer. Basic parameters: from 40 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Prospective Study of Gastric Cancer Screening Based on Fecal Multi-Target DNA Analysis Combined With a Risk Questionnaire

Overview

This is a prospective study designed to evaluate the efficacy of a multi-target fecal DNA test for the early detection of gastric cancer. The test combines Helicobacter pylori gene detection with analysis of fecal methylated DNA markers. The primary objective is to assess whether each method, individually or in combination, can facilitate earlier diagnosis of gastric cancer. All participants will undergo the multi-target fecal DNA test and complete the gastric cancer risk questionnaire.

Detailed description

Sample Selection:

The study will be conducted in selected communities within Tongling City, with a total of 10000-15000 residents recruited

Participants Recruitment:

* Participation is voluntary. All subjects must provide written informed consent at the time of recruitment. * Well-trained investigators will conduct face-to-face interviews to administer the gastric cancer risk questionnaire.

Tests and Follow-up:

* Initial Screening: All participants will provide a stool sample for the multi-target DNA analysis (including H. pylori susceptibility testing and methylated DNA markers) and complete a questionnaire. * Definition of Screening Positive: A participant will be considered screening positive if they test positive on the fecal multi-target DNA test or are identified as high-risk through the questionnaire. * Diagnostic Workup: All screening-positive individuals will be referred for a confirmatory diagnostic workup. Briefly, the endoscopist will conduct a fiberoptic endoscopy and perform a pathological biopsy. * Follow-up: Screening-positive individuals who are not diagnosed with gastric cancer in the first year will be entered into an annual follow-up program. * Biobanking: Residual fecal samples will be stored at the biobank of Fudan University Shanghai Cancer Center for future biomarker research.

Primary outcome measures

  • Sensitivity and specificity of the fecal multi-target DNA test and questionnaire screening for gastric cancer [Time frame: 2 years]
Secondary outcome measures (4)
  • Positive and negative predictive values of the fecal multi-target DNA test and the questionnaire screening method [Time frame: 2 years]
  • Number needed to screen to identify one gastric cancer [Time frame: 2 years]
  • Early diagnosis rate of gastric cancer [Time frame: 2 years]
  • Diagnosis rate of precancerous lesions associated with gastric cancer [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

  • Age ≥40 years, male or female.
  • No contraindications to endoscopy and able to cooperate with endoscopy.
  • Patients must be able to fully understand the informed consent form and be able to sign the informed consent form in person.

Exclusion criteria

  • A history of diagnosed gastric cancer or other malignant tumors of the digestive tract.
  • Comorbid severe underlying conditions (e.g., severe cardiopulmonary insufficiency, liver or renal failure, etc.) that are likely to result in a short life expectancy or render long-term follow-up impractical.
  • Severe mental illness or incapacity to participate in the study due to lack of civil behavior.
  • Pregnant or breastfeeding women.
  • Other conditions that the investigator deems inappropriate for participation in the study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

China · 1 center
  • People's Hospital of Tongling City — Tongling

Identifiers

NCT: NCT06943807 · 2410-Exp079

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗